(NASDAQ: CDXS) Codexis's forecast annual revenue growth rate of 13.03% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.79%, and while it is forecast to beat the US market's average forecast revenue growth rate of 12.37%.
Codexis's revenue in 2026 is $77,679,000.On average, 10 Wall Street analysts forecast CDXS's revenue for 2026 to be $8,252,354,450, with the lowest CDXS revenue forecast at $7,776,442,396, and the highest CDXS revenue forecast at $8,715,563,836. On average, 9 Wall Street analysts forecast CDXS's revenue for 2027 to be $9,794,852,656, with the lowest CDXS revenue forecast at $8,671,104,496, and the highest CDXS revenue forecast at $12,521,984,228.
In 2028, CDXS is forecast to generate $12,572,356,880 in revenue, with the lowest revenue forecast at $9,905,234,467 and the highest revenue forecast at $16,390,822,905.